Vikas Vij appointed as new CEO of IOL Chemicals and Pharma

Mr Vikas Vij takes over from Dr Sanjay Chaturvedi.

Published On 2023-04-05 09:01 GMT   |   Update On 2023-04-05 09:35 GMT
Advertisement

Ludhiana: IOL Chemicals and Pharmaceuticals Limited (IOL), a manufacturer of pharmaceutical (APIs) and specialty chemicals, has appointed Mr Vikas Vij as the new Chief Executive Officer, with effect from 3rd April 2023. Mr Vij’s role is expected to aid the company to bolster growth across domestic and international markets by leading IOL’s portfolio enhancement and efficiencies.

Mr Vikas Vij has a techno-commercial background with a nuanced understanding of Active Pharmaceutical Ingredients (API), Finished Dosage Forms (FDF), Custom Pharmaceutical Services (CRAMS), specialty chemicals, and operations from his previous leadership roles across the pharma value chain. He was previously associated with Cipla as the Senior Vice President of API and Access Business Units. In his career spanning over 30 years, he has donned various roles in Ranbaxy, GVK Biosciences, Alembic Pharmaceuticals, Sun Pharma, and Apollo Hospitals.

Advertisement

Mr Vikas Gupta – Joint Managing Director of IOL Chemicals and Pharmaceuticals said, “I am delighted to welcome Mr Vikas Vij as CEO of IOL Chemicals and Pharmaceuticals. He is a demonstrated leader who brings in tremendous capabilities of driving sales and scaling businesses in the pharmaceutical and specialty chemicals domains. We are confident that his experience across the board will empower us to drive transformational growth for IOL nationally as well as in advanced and emerging markets.”

On his appointment, Mr Vikas Vij – Chief Executive Officer of IOL Chemicals and Pharmaceuticals said, “I am excited to work with the dynamic workforce at IOL to drive its next phase of growth. It is a great privilege to lead a company that is making a significant impact on people’s lives and to the growth of the Indian Pharmaceutical Industry.”

Mr Vikas Vij takes over from Dr Sanjay Chaturvedi. 

IOLCP has wide presence across major therapeutic categories like, Pain Management, anti- convulsants, anti-diabetes, anti-cholesterol and anti-platelets.

Read also: IOL Chemicals and Pharma gets EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News